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Abstract
Introduction: The developmental origins of disease or fetal programming model predicts that
intrauterine exposures have life-long consequences for physical and psychological health. Prenatal
programming of the fetal hypothalamic-pituitary-adrenal (HPA) axis is proposed as a primary
mechanism by which early experiences are linked to later disease risk.
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Areas covered: This review describes the development of the fetal HPA axis, which is
determined by an intricately timed cascade of endocrine events during gestation and is regulated
by an integrated maternal-placental-fetal steroidogenic unit. Mechanisms by which stress-induced
elevations in hormones of maternal, fetal, or placental origin influence the structure and function
of the emerging fetal HPA axis are discussed. Recent prospective studies documenting persisting
associations between prenatal stress exposures and altered postnatal HPA axis function are
summarized, with effects observed beginning in infancy into adulthood.
Expert commentary: The results of these studies are synthesized, and potential moderating
factors are discussed. Promising areas of further research highlighted include epigenetic
mechanisms and interactions between pre and postnatal influences.
Keywords
placenta; cortisol; CRH; fetal programming; prenatal stress; HPA axis; pregnancy; development

1.

Introduction

Author Manuscript

The fetal period is a critical window of development, during which the architecture of the
brain and other organ systems are fundamentally shaped. Within the first month of gestation,
regions of the central nervous system are already formed and differentiated. Prolific
neurogenesis occurs, with the majority of the brain’s billions of neurons produced by midgestation [1]. An intricately timed sequence of organizational processes ensues, including
neuronal migration, differentiation, synaptogenesis, apoptosis, and myelination [2]. Because
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the developing fetal brain is plastic, it is highly susceptible to in utero exposures and
experiences.
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The developmental origins of disease or fetal programming model predicts that early
exposures to a variety of adverse events and signals have life-long consequences for physical
and psychological health [3, 4]. Programming refers to the effects of an environmental signal
acting during a sensitive developmental period to influence the construction of specific
organ systems [3–5]. The developing fetus is sensitive and responsive to maternal
nutritional, vascular, immune, and endocrine signals that convey information about the
quality of the external environment. In response to these signals, the fetus adjusts its
developmental trajectory to prepare for its anticipated life after birth. If signals convey
conditions of deprivation or stress, the fetus may accelerate or reduce its growth, or shift
resources to benefit certain systems at a cost to other systems [6, 7]. These developmental
alterations may be adaptive. For instance, if the postnatal environment matches that
predicted by the prenatal environment, the infant may be well-equipped for his or her
environment and may thrive. If there is a mismatch, the risk for disease may increase [4, 5,
8].

Author Manuscript

During fetal life, the hypothalamic-pituitary-adrenal (HPA) axis is under construction and
therefore susceptible to prenatal programming influences. The fully mature HPA axis
mobilizes the body’s physical and psychological resources in response to stress and
regulates many homeostatic systems in the body, including the metabolic, cardiovascular,
immune, reproductive, and central nervous systems. Given the central role of the HPA axis
in many survival functions and links between HPA axis dysregulation and disease [9–15],
programming of this system during fetal life is proposed as a primary mechanism by which
early experiences are linked to later health outcomes [3, 16–22].

Author Manuscript

In this review, we examine evidence supporting the hypothesis that prenatal stress exposures
shape the developing fetal HPA axis and represent a primary fetal programming mechanism.
First, we describe the prenatal endocrine milieu in which the fetal HPA axis develops. We
then delineate mechanisms by which fetal exposure to prenatal stress may influence the
structure and function of the emerging HPA axis. Finally, we summarize existing literature
concerning the effects of prenatal stress on postnatal HPA axis functioning, spanning infancy
to adulthood. There is a well-established non-human animal literature documenting the
programming influences of prenatal stress on offspring outcomes, including HPA axis
functioning [23–26]. Human gestational physiology and fetal HPA axis development differ
even from that of closely related nonhuman primates, thereby limiting the generalizability of
animal models [27, 28]. Thus, this review will focus solely on studies of prenatal stress and
fetal HPA axis development in humans.

2.

Biological stress system
The human biological “fight or flight” stress response is triggered under conditions of threat
to homeostasis and involves activation of the HPA axis, in coordination with the locus
ceruleus-norepinephrine (LC-NE)/sympathetic and immune systems. The primary regulator
of the HPA axis is the 41-amino acid neuropeptide corticotropin-releasing hormone (CRH).
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CRH-producing neurons in paraventricular nucleus of the hypothalamus are innervated by
afferent projections from multiple brain regions, including the brain stem, lamina terminalis,
extra-PVN hypothalamic nuclei, and limbic structures, which respond to different physical
and emotional stressors [29–31; see Figure 1]. CRH is secreted, along with argininevasopressin (AVP), into the hypophyseal portal blood, via axons projecting to the median
eminence. CRH binds to its receptors on corticotropes of the anterior pituitary, stimulating
production of the 31K dalton prohormone proopiomelanocortin (POMC). POMC is cleaved
by enzymes into adrenocorticotrophic hormone (ACTH) and other bioactive peptides. ACTH
enters the bloodstream and induces secretion of the glucocorticoid steroid hormone cortisol
from the zona fasciculata of the adrenal cortex (see Figure 1). This cascade of hormone
events mobilizes the body’s physiological and psychological resources to cope with the
stressor and maintain homeostasis.

Author Manuscript
Author Manuscript

Circulating cortisol exerts its effects by binding to two types of receptors, the type I, highaffinity mineralocorticoid receptor (MR), and the type II, low-affinity glucocorticoid
receptor (GR). Cortisol has a 10-fold higher affinity for MRs than for GRs, so at basal
concentrations of cortisol, MRs are occupied and GRs remain largely unoccupied [32]. MRs
are proposed to regulate the tonic actions of cortisol, including its normative diurnal rhythm
and the sensitivity of the stress response, whereas GRs are increasingly occupied during
periods of elevated cortisol in response to stress [10, 32–34]. The effects of stress-induced
elevations in cortisol include activation and regulation of cardiovascular and immune
systems, utilization of energy stores and gluconeogenesis, inhibition of feeding,
reproductive, and growth functions, and enhancement of memory and attentional processes
[9, 10, 18, 29, 35–37]. High levels of circulating cortisol inhibit further HPA activity by
binding to GRs and MRs at the level of the hypothalamus, pituitary, and hippocampus [10,
30]. Under normal conditions, this negative feedback loop terminates the stress response,
because its adaptive function is to respond to and prepare for immediate challenges.
Prolonged or chronic stress exposures may have adverse effects and result in dysregulation
of the HPA axis [9, 36, 38, 39].

Author Manuscript

HPA axis dysregulation is associated with a variety of pathological conditions, including
metabolic and cardiovascular disease, hypertension, obesity, osteoporosis, altered
gastrointestinal and immune function, sleep disturbances, and affective disorders [9, 11–15,
35, 37, 40–45]. Links between HPA axis functioning and disease states are likely complex
and bidirectional, with HPA axis functioning serving as a risk factor for and/or a
consequence of disease. Prospective, longitudinal studies provide evidence that HPA axis
dysregulation precedes certain physical and psychological conditions. Higher diurnal
cortisol output is predictive of increasing mental health symptoms across childhood [46],
and higher cortisol awakening responses have been shown to predict onsets of anxiety and
depressive disorders during adolescence and adulthood [47–52]. Blunted patterns of diurnal
cortisol output have been associated with higher body mass index both concurrently and
longitudinally during adolescence [53]. Higher diurnal cortisol output also prospectively
predicts reduced hippocampal volume and memory deficits [54] as well as increased risk of
cardiovascular-related mortality in older adults [55].
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Maternal-placental-fetal stress system
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Examining the link between prenatal stress and fetal HPA axis development requires an
understanding of the dramatic changes that occur in both the maternal and developing fetal
stress systems during the prenatal period. The growth of a new organ, the placenta, is
primarily responsible for these changes. The placenta is the interface and area of exchange
of signals or information between the maternal and fetal compartments. The placenta
additionally produces its own hormones, most of which are identical to those produced in
endocrine tissue of the non-pregnant adult [56, 57]. These placental hormones bind to
maternal hormone receptors and act as allocrine factors, adjusting maternal physiology to
benefit both mother and fetus [58]. Among the many hormones produced by the placenta is
CRH, the primary regulator of the stress response system. CRH mRNA is expressed in the
placenta by the seventh week of gestation [59], is identical to hypothalamic CRH in
structure, immunoreactivity, and bioreactivity, and is released into both maternal and fetal
compartments [59–63]. Placental CRH is a primary regulator of stress hormone production
during pregnancy and both influences and is influenced by maternal and fetal stress signals.
As such, the prenatal stress response system may be best conceptualized as an integrated
maternal-placental-fetal steroidogenic unit [58; see Figure 2].
3.1

Changes in the maternal stress system

Author Manuscript

Over course of gestation, maternal production of stress peptides and hormones increases
several-fold, largely as a result of placental CRH production. Concentrations of circulating
CRH in the maternal plasma are almost exclusively of placental origin. The minute
quantities of maternal hypothalamic CRH released into circulation are rapidly degraded and
largely undetectable [58, 64]. Placental CRH production rises exponentially over gestation
and increases in maternal plasma up to 1,000 times its non-pregnant level [65, 66]. By the
end of gestation, maternal placental CRH levels are equivalent to those observed in the
hypothalamic system only during acute psychological stress [67].

Author Manuscript

Increased unbound placental CRH in maternal plasma stimulates the synthesis and release of
maternal ACTH from the anterior pituitary and downstream production of cortisol from the
adrenal glands [68–71]. Maternal plasma cortisol levels increase 3–5-fold over the course of
gestation, reaching levels comparable to those observed in Cushing’s disease and certain
psychopathological conditions [64, 66]. Unlike the negative feedback function of cortisol on
CRH expression in the hypothalamus, maternal cortisol stimulates expression of CRH in the
placenta [70]. A positive feedback loop is established, allowing for the simultaneous
increase of placental CRH, ACTH, and cortisol in the maternal compartment over the course
gestation [59, 66, 68, 70, 71; see Figures 2 and 3]. The maternal HPA axis is still subject to
negative feedback inhibition, and as pregnancy advances towards term, increased levels of
these hormones further blunt maternal HPA axis responsiveness to physiological and
psychological stressors [72–78]. This dampening in stress responsivity likely serves an
adaptive purpose, protecting the mother and her fetus from the deleterious effects of
environmental stressors [72, 79, 80].
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Developing fetal stress system
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Because the fetal stress system is immature, it relies heavily upon maternal and placental
inputs, functioning more so as an endocrine network than a linear axis [81]. The structures
of the emerging fetal HPA axis undergo tremendous growth and organization during the
prenatal period, and as gestation advances, fetal stress hormone production is increasingly
evident.

Author Manuscript

The fetal hypothalamus forms from the ventral diencephalon and is differentiated by 9–10
weeks’ gestation (see refs. 82, 83). The primordium of the anterior pituitary, Rathke’s pouch,
is formed from an invagination of oral ectoderm and is first evident at approximately 5
weeks’ gestation (see refs. 58, 84–87). The hypothalamic-hypophyseal portal system is
intact as early as 11 weeks’ gestation [88]. CRH immunoactivity and bioactivity are
detectable in fetal hypothalamic tissue extracts as early as 12–13 weeks’ gestation, with
bioactivity increasing as a function of gestational age [89]. CRH-immunoreactive fibers are
present in the median eminence by 14–16 weeks’ gestation [90], and CRH immunoactivity
is present in the fetal pituitary from 12 weeks’ gestation onwards [89]. The fetal
hypothalamus therefore has the capacity to stimulate pituitary ACTH production from early
in the second trimester. In vitro, fetal pituitary corticotrophs secrete significant amounts of
ACTH as early as 8 weeks’ gestation [91, 92], and administration of synthetic CRH
stimulates ACTH secretion by the pituitary as early as 14 weeks’ gestation [93, 94]. The
extent to which endogenous fetal hypothalamic CRH is involved in regulating ACTH release
in vivo remains uncertain [58]. Examination of endocrine profiles in preterm infants
suggests that sequential release of hypothalamic CRH, ACTH and cortisol may not be
established until late in gestation [95, 96].

Author Manuscript
Author Manuscript

The fetal adrenal cortex arises from the intermediate mesoderm. The adrenal primordium
forms posteromedial to the urogenital ridge and is distinguishable at 33 days’ postconception [97–99]. By 8 weeks’ gestation, the distinct zones of the cortex are apparent, and
by 9 weeks’ gestation, the cortex is completely encapsulated [27, 92, 97, 99]. The fetal
adrenal cortex is active beginning early in gestation and is one of the most highly
vascularized fetal organs [27]. Adrenal steroid hormones are involved in the regulation of
intrauterine homeostasis and the maturation of organ systems [22, 27, 100]. De novo
synthesis of cortisol from its precursor cholesterol requires the presence of specific
steroidogenic enzymes, including 3β-hydroxysteroid dehydrogenase/Δ4−5 isomerase (3βHSD). A recent examination of first trimester fetal adrenals documented by
immunohistochemistry a transient expression of 3β-HSD from approximately 7–10 weeks’
gestation [92]. Ex vivo tissue culture revealed cortisol synthesis regulated by ACTH and
negative feedback apparent at the anterior pituitary. Therefore, early in gestation, de novo
production of cortisol from cholesterol likely occurs briefly, which may function to regulate
female sexual differentiation via inhibition of adrenal androgen production [92]. During
most of the second trimester, fetal adrenal expression of 3β-HSD is suppressed [101–103].
From approximately 23–24 weeks onward, 3β-HSD and other requisite enzymes are again
apparent, and cortisol production increases as gestation advances [101–103].
In addition to the patterning of steroidogenic enzymes, placental factors regulating fetal
exposure to maternal cortisol are hypothesized to influence the timing of fetal pituitaryExpert Rev Endocrinol Metab. Author manuscript; available in PMC 2019 January 16.
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adrenal activity. From early to mid-gestation, transfer of maternal cortisol to the fetus may
function to suppress fetal ACTH production [104]. As gestation advances, increasing levels
of the placental enzyme 11β-hydroxysteroid dehydrogenase 2 (11β-HSD-2) oxidize
maternal cortisol into its metabolite cortisone, which does not act on glucocorticoid
receptors [105–110]. Reduced maternal cortisol in the fetal circulation may then disinhibit
the fetal pituitary, resulting in increased ACTH production [104, 107]. ACTH secreted from
the fetal pituitary is the primary regulator of fetal adrenocortical development, stimulating
the proliferation of adrenocortical cells in vivo [27].

Author Manuscript

However, rising levels of fetal cortisol over the second half of gestation [111–113] are not
paralleled by large increases in fetal ACTH [111, 114]. Evidence suggests that placental
hormones, particularly placental CRH, play a central role in regulating fetal adrenal
development. Both the fetal pituitary and adrenal glands express CRH receptors [115, 116].
In vitro, CRH up-regulates ACTH receptor expression in isolated fetal adrenal cells [117].
Increasing levels of placental CRH could therefore enhance adrenal responsiveness to
ACTH, promoting adrenal cortisol synthesis despite the limited availability of circulating
fetal ACTH [117]. Placental CRH also may directly regulate adrenal cortisol production, as
CRH stimulates cortisol synthesis and expression of requisite steroidogenic enzymes in
isolated fetal adrenal cells [118, 119]. Increased fetal cortisol would in turn increase
placental CRH levels, forming a positive feedback loop parallel to that of maternal cortisol
and placental CRH [27, 70]. Higher levels of CRH in the umbilical vein as compared to the
umbilical artery suggest that CRH in the fetal circulation is largely of placental origin [61].

Author Manuscript

Although the likely multiple mechanisms by which fetal cortisol production is regulated are
not fully understood, escalation of fetal cortisol production from the end of the second
trimester through the third trimester is evident [111–113]. By 30 weeks, the fetal adrenal
cortex resembles a rudimentary form of the adult adrenal cortex [120]. Late in pregnancy, at
approximately 34–35 weeks’ gestation, levels of 11β-HSD-2 decrease [107, 108, 121],
allowing for greater transfer of maternal cortisol into the fetal compartment. Increased
maternal cortisol in the fetal circulation would suppress fetal ACTH production. The
increased transfer of maternal cortisol to the fetus is thought to constitute a back-up
mechanism to ensure fetal organ maturation and may explain why fetuses with
glucocorticoid deficiencies are born without signs of organ immaturity [27, 58]. By term,
approximately 75% of the cortisol in fetal circulation is of fetal origin, with the remaining
25% of maternal origin [105]. In addition to ensuring adequate maturation of fetal organ
systems, elevated maternal and fetal cortisol late in gestation may act to influence the timing
of parturition [27, 70, 100, 121, 122].

Author Manuscript

4.

Fetal exposure to prenatal stress hormones
Fetal exposure to maternal and placental stress hormones is considered a primary biological
pathway by which various forms of prenatal psychological and biological stress influence
the development of the fetal HPA axis. Maternal cortisol and placental CRH are key prenatal
stress hormones which may program the emerging fetal HPA axis. The maternal-placentalfetal steroidogenic unit produces massive amounts of these stress hormones during
pregnancy. While exponential increases in these hormones are normative and necessary for
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successful gestation and parturition, the fetus is vulnerable to further stress-induced
increases in these hormones. In cases of extreme stress to the system and rapidly
accelerating levels of stress hormones, especially placental CRH, preterm birth may result
[66, 123, 124]. Increasing evidence suggests that stress-induced increases in hormones also
exert programming influences on fetal HPA axis development independent of birth
phenotype.
4.1

Exposure to maternal cortisol

Author Manuscript

The effects of elevated maternal cortisol appear to be dependent upon the timing of
exposure. As previously stated, the fetus is less protected from maternal cortisol during early
and late gestation, when placental 11β-HSD-2 levels are lower [105–109, 121]. Excess
maternal cortisol during early to mid-gestation appears to exert negative effects on the fetus,
whereas elevated maternal cortisol near term is beneficial, promoting fetal organ maturation
and enhanced neurodevelopment [125–129]. Although 11β-HSD-2 limits fetal exposure to
maternal cortisol as gestation advances, it is only partial barrier [130, 131], with
approximately 15% of maternal cortisol crossing through the placenta unmetabolized [106,
131, 132]. Mid to late-gestational maternal and fetal cortisol levels are correlated, with
approximately 40% of their variance shared [130, 131]. Additional associations have been
documented between maternal cortisol and amniotic fluid cortisol [133] and between
maternal and neonatal ACTH and cortisol levels at birth [134].

Author Manuscript

Because some maternal cortisol does reach the fetus, elevations in maternal cortisol in
response to physical or psychological stress may subsequently elevate cortisol levels in the
fetal circulation [106, 111, 130, 131, 135]. Increased maternal stress also may increase fetal
exposure to cortisol by downregulating placental 11β-HSD-2 activity, thus allowing a
greater proportion of maternal cortisol to cross into the placenta and then enter fetal
circulation. Several key biological stress signals act to downregulate placental 11β-HSD-2,
including catecholamines [136], proinflammatory cytokines [137, 138], and hypoxic factors
[139]. Prenatal maternal anxiety and depressive symptoms are respectively associated with
reduced placental 11β-HSD-2 gene expression and activity [140]. Decreased 11β-HSD-2
activity may account for the greater concordance observed between maternal and amniotic
fluid cortisol as a function increased maternal anxiety [141].

Author Manuscript

Exposure to excessive concentrations of cortisol could alter glucocorticoid receptor density
and function at each level of the fetal HPA axis, thereby calibrating the sensitivity of the
system to feedback mechanisms [23, 142]. Glucocorticoid receptors are highly expressed
throughout the developing brain, particularly so in regions providing excitatory (e.g.,
amygdala) and inhibitory (e.g., hippocampus) inputs to the HPA axis [22, 24, 30, 143–147].
GRs and MRs are abundant in the hippocampus [10, 32], with both receptor types expressed
in this region as early as 24 weeks’ gestation [147]. Prenatal glucocorticoid exposure is
associated with decreased hippocampal GR and MR density in non-human animals,
resulting in decreased negative feedback regulation of the HPA axis [10, 142, 147–150].
Additional findings from animal models indicate that excess glucocorticoids alter the density
of MRs and GRs and increase production of CRH in the amygdala, with increased forward
drive to the axis [25, 142, 148]. In humans, exposure to elevated maternal cortisol early in
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gestation is associated with increased volume of the right amygdala in female children [127].
The balance of GRs and MRs in the hippocampus and other brain regions is critical to HPA
axis sensitivity, drive, and inhibition, with a GR/MR imbalance resulting in dysregulation of
the axis and is implicated in depression and other psychopathological conditions [10, 151].
4.2

Exposure to placental CRH
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Like the hypothalamus, the placenta produces CRH in response to stress. Unlike the negative
feedback influence of cortisol on hypothalamic CRH expression, maternal and fetal cortisol
stimulate placental CRH expression, constituting parallel positive feedback loops [27, 59,
64, 68, 70]. Elevations in maternal cortisol may therefore act on fetal development indirectly
through increased placental CRH production. In vivo, elevated levels of maternal cortisol
early in gestation are associated with accelerated trajectories of placental CRH [66, 152].
CRH is also released from cultured human placental cells in a dose-response manner to a
number of other major biological stress signals, including catecholamines, proinflammatory
cytokines, and angiotensin-II [153, 154]. Consistent with these in vitro studies, stress-related
intrauterine conditions such as reduced uterine blood flow, nutrient restriction, and infection
are associated with increases in placental CRH [155–157]. Elevated placental CRH levels
also are observed in women with higher maternal pregnancy-specific anxiety [158],
perceived stress [159] and depressive symptoms [160–162], and in women with lower social
support from family [163]. Thus, placental CRH may represent an integrative pathway by
which various prenatal stressors of both maternal and fetal origin shape the developing fetal
HPA axis.
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As previously discussed, placental CRH likely acts to increase fetal cortisol production, both
directly, by stimulation of the fetal adrenals, and indirectly, by increasing fetal adrenal
responsiveness to ACTH [115–119]. Upregulated placental CRH via any of the biological
stress signals promoting its production could therefore induce exaggerated fetal adrenal
cortisol production or program the sensitivity of the adrenal glands to ACTH [70, 111, 118].
Elevated placental CRH in the fetal circulation presumably permeates the immature fetal
blood-brain barrier [164], where CRH receptors are widely expressed from 13 weeks’
gestation [165]. CRH mRNA-expressing neurons are particularly abundant in the amygdala
and hippocampus, which provide excitatory and inhibitory input to the hypothalamus,
respectively [30, 144]. Animal models indicate that excess circulating CRH upregulates
CRH and CRH receptor mRNA expression in these regions, with consequences for neuronal
function and integrity [24, 142, 144]. For example, administration of CRH to the brains of
immature rodents results in progressive loss of hippocampal neurons, which may impair
hippocampal negative feedback regulation of the HPA axis [144]. Several human studies
provide additional support for programming effects of placental CRH on the fetal brain,
linking placental CRH exposures with fetal neurodevelopment [166–168] and with stressrelated outcomes in infancy and childhood [169, 170].

Author Manuscript

5.

Prenatal stress exposures and postnatal HPA axis function
Programming of the developing fetal HPA axis is proposed as a plausible mechanism by
which prenatal stress influences offspring physiological and psychological outcomes,
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including risk for cardiovascular and metabolic disease, compromised immune function, and
mental disorders [18–21, 171]. We review here studies in which postnatal HPA axis
functioning is the direct outcome of interest and in which maternal prenatal stress is indexed
directly rather than inferred from birth phenotype (for reviews of studies linking shortened
gestation and small size at birth with altered HPA axis functioning, see refs. 21, 172, 173).
One challenge that limits the ability to draw firm conclusions about persisting influences of
prenatal stress exposures on HPA axis functioning is the broad range of measures of both
prenatal stress and HPA axis functioning utilized. For this review, we conceptualize prenatal
stress as encompassing both stress exposures, such as life events, and different physiological
or psychological responses to stress, such as cortisol levels or symptoms of anxiety or
depression [174]. In characterizing HPA axis functioning, some studies have considered
basal cortisol levels at a single time point. Other investigations have measured cortisol
response to laboratory or naturalistic stressors. Saliva samples are collected prior to the
stressor (baseline) and at several intervals post-stressor to examine the peak and recovery of
the cortisol response. Finally, several studies have evaluated profiles of diurnal cortisol
output. In the mature HPA axis, cortisol levels follow a normative diurnal rhythm, with a 50–
100% increase in levels observed upon awakening (termed the cortisol awakening response,
or CAR), peak levels approximately 30–45 minutes after awakening, and a decline in levels
across the remainder of the day [175–177]. Table 1 summarizes these existing studies, with
findings observed in the neonate, infant, child, adolescent, and adult. While variable in their
methodologies and results, these studies provide strong support for the notion that prenatal
stress programs the developing fetal HPA axis, with persisting consequences for its function.

Author Manuscript
5.1

Neonate
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Several studies have assessed levels of neonatal cortisol upon or shortly after delivery.
Neonates exposed to elevated levels of maternal depressive symptoms over the latter half of
gestation exhibited higher levels of ACTH as compared to infants exposed to low levels of
maternal depressive symptoms [178]. Two other investigations found that neonates of
mothers with elevated prenatal depressive symptoms had higher levels of urinary cortisol
[179, 180]. Only one known study to date has examined cortisol responses to a stressor in a
neonatal sample [128]. Elevated maternal cortisol from 21 to 35 weeks’ gestation was
associated with an exaggerated neonatal salivary cortisol response to the painful stress of the
heel-stick blood draw, with the strongest effects observed at 25 weeks’ gestation.
Cumulatively, these studies suggest that prenatal stress predicts heightened HPA axis activity
during the neonatal period.
5.2

Infant

Author Manuscript

Studies that have assessed cortisol responses to routine stressors in the first several months
of infancy and have documented elevated cortisol responses in stress-exposed infants. Stroud
et al. [181] measured 1-month-old infants’ cortisol responses to a neurobehavioral
examination in which the infant is observed and handled during periods of sleep,
wakefulness, crying, and non-crying. Infants of mothers with prenatal depressive disorders
demonstrated higher baseline cortisol levels and greater responses to the stressor, as
compared to infants of mothers who were not depressed during their pregnancy. This effect
was observed primarily in female infants. Furthermore, placental 11β-HSD-2 methylation
Expert Rev Endocrinol Metab. Author manuscript; available in PMC 2019 January 16.
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appeared to moderate these effects. Among those infants exposed to prenatal maternal
depression, decreases in 11β-HSD-2 methylation were associated with increases in baseline
cortisol. Tollenaar et al. [182] similarly found that higher maternal pregnancy-related anxiety
predicted higher infant cortisol responses to a bathing session at 5 weeks of age.

Author Manuscript

There is some evidence that after the first several months of life, a developmental shift in
HPA axis functioning occurs, and a period of hyporesponsiveness to stress is observed [183].
Several studies have measured cortisol responses to vaccinations or laboratory stressors in
infants ranging from 2 to 17 months of age. These investigations, while diverse in their
findings, on average suggest that infants exposed to higher levels of prenatal stress may
present with greater HPA axis hypoactivity at this stage of development. A few of these
studies have assessed infant cortisol responses to vaccination. Higher maternal pregnancyrelated anxiety was associated with decreased infant cortisol reactivity to vaccination in 2month-old infants [182]. Alternatively, Braithwaite et al. [184] found no effect of maternal
prenatal depressive symptoms on cortisol response to vaccination in 2–4-month-old infants.
Other studies have examined infant cortisol responses to standardized laboratory stressors.
Rash [185] measured the effects of maternal prenatal diurnal cortisol output on cortisol
response to a frustration task in 6-month-old infants. Infants who exhibited decreases in
cortisol in response to the task (as opposed to an increase) were exposed to a flatter maternal
diurnal profile (less of a decline in cortisol over the course of the day) at 15 weeks’
gestation. Another investigation examined cortisol response to the stressful still-face
procedure in 7-month-old infants of mothers with and without prenatal anxiety disorders
[186]. Differences in infant cortisol profiles only emerged 25–40 minutes post-stressor;
infants of mothers without prenatal anxiety exhibited decreases in cortisol, and infants of
mothers with prenatal anxiety displayed non-significant increases in cortisol. Finally, two
studies have examined infant cortisol responses to a maternal separation paradigm [140,
182]. Higher maternal pregnancy-related anxiety was associated with a lower cortisol
response in 12-month-old infants [182], and higher amniotic fluid cortisol was associated
with higher baseline cortisol and a blunted cortisol response in 17-month-old infants [140].
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5.3

Child

Author Manuscript

Multiple studies have examined either cortisol response or diurnal cortisol output in
childhood. All of these studies document hyperactivity of the HPA axis in children exposed
to higher levels of prenatal stress. Elevated levels of maternal prenatal depression and
anxiety predicted higher cortisol levels across a series of tasks in 2–5-year-old female
children, with no differences observed in profiles of response to the tasks [187]. Higher
prenatal maternal early morning salivary cortisol and pregnancy related-anxiety were
associated with higher overall cortisol levels in 4–6-year-old children on the day of a
vaccination [188] and higher overall cortisol levels in 5-year-old children on school days
[189]. Another study measured 10-year-old children’s cortisol responses to a laboratory
stressor and identified three cortisol profiles over the stressor: low levels with no response,
moderate levels with no response, and high levels with response [190]. Prenatal maternal
intimate partner violence increased the likelihood of membership in the high response group,
as compared to the low and moderate flat groups. One additional study measured diurnal
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cortisol output in 10-year-old children and found that higher maternal prenatal anxiety was
associated with higher awakening cortisol levels [191].
5.4

Adolescent

Author Manuscript

A few investigations have extended examination of offspring HPA axis functioning into the
adolescent period. Two studies assessed adolescents’ diurnal cortisol output and documented
hypoactivity in adolescents exposed to prenatal stress. Higher maternal prenatal anxiety and
depression predicted an altered pattern of diurnal salivary cortisol in 15-year-old children,
reflected in a reduced cortisol awakening response and a flatter cortisol decline (smaller
decrease from awakening to evening) over the day [192]. Similarly, elevated prenatal
maternal anxiety was associated with a flatter diurnal cortisol decline in 14–15-year-old
children [193]. One additional study defined prenatal stress as exposure to a disaster during
pregnancy [194]. A birth cohort of 14-year-old Finnish twins whose mothers were pregnant
during the Chernobyl disaster was compared with a reference group of twins whose mothers
were pregnant one year after the disaster. Cortisol levels measured once upon arrival to a
laboratory visit were higher in adolescents whose mothers were in their second or third
trimester during the Chernobyl disaster, as compared to non-exposed adolescents.
5.5

Adult

Author Manuscript

Finally, one known study has examined the effects of prenatal stress, measured by maternal
experience of a major negative life event during pregnancy, on multiple measures of HPA
axis activity in adulthood [195]. Young adult children who reported that their mothers had
experienced a negative life event during their pregnancy were compared with an agematched control group. As compared to the control group, the prenatal stress-exposed group
exhibited hypoactivity in several domains, reflected in lower pre-stressor cortisol levels and
lower cortisol levels during pharmacological stimulation of the pituitary via an ACTH1–24
stimulation test. However, the prenatal stress-exposed group also exhibited increased
reactivity to the stressor, with greater increases in cortisol in response to the stressor. No
differences in diurnal cortisol output were exhibited between the two groups. A limitation of
this investigation was that prenatal maternal negative life events were obtained
retrospectively by adult children in communication with their mothers at the time of
assessment.
5.6

Synthetic glucocorticoid exposure

Author Manuscript

Administration of synthetic glucocorticoids (GCs) is the standard of care for pregnant
women at risk for premature delivery between 24 and 34 weeks’ gestation, because this
treatment effectively reduces mortality and promotes lung maturation among infants born
preterm [196, 197]. Synthetic GCs are not metabolized by placental 11β-HSD-2 and
therefore readily cross into the placenta, where they act on developing fetal organ systems
[198, 199]. Evidence indicates that prenatal synthetic GC exposures are associated with
dysregulated postnatal HPA axis function. For example, compared to non-exposed preterm
neonates, exposed preterm neonates exhibit no increases or decreases in cortisol in response
to a heel-stick blood draw [200–203]. Because determining if preterm delivery will actually
occur is difficult and imprecise, many women who receive synthetic GCs often go on to
deliver beyond 37 weeks’ gestation [204]. One study demonstrated that full-term neonates
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exposed to synthetic GCs prenatally exhibited a larger cortisol response to the heel-stick
procedure, as compared to non-exposed neonates [205]. These effects appear to persist into
childhood, with prenatal synthetic GC exposure predicting greater increases in cortisol in
response to a laboratory stressor in term-born children [206] and in preterm-born
adolescents [207]. Several studies have also documented that children and adolescents
exposed to prenatal synthetic GCs display alterations in diurnal cortisol output, evident in an
absence of a CAR [207, 208] and a flatter decline in cortisol over the day [208]. This
literature provides additional support for the programming effects of excess glucocorticoids
on long-term HPA axis function.

6.

Expert commentary

Author Manuscript

A growing body of research has linked prenatal stress exposures with HPA axis functioning
from infancy into adulthood. HPA axis dysregulation in prenatal stress-exposed individuals
has been documented at multiple levels of functioning, including diurnal rhythms and
responses to stress. It remains unclear as to how these different aspects of HPA axis function
may interact or reflect similar or different markers of risk [209], particularly since studies
have primarily focused on either diurnal rhythms or responses to stress and not their
synergistic effects. Additionally, there is no clear consensus within the literature as to
whether prenatal stress is associated with hyperactivity or hypoactivity of the axis. The wide
variation in methodologies employed across these studies may in part account for the
apparent inconsistency in findings (see ref. 209 for a relevant discussion).

Author Manuscript
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It is also plausible that these discrepancies reflect meaningful developmental patterns. First,
there is evidence that both diurnal cortisol output and cortisol response to stress vary over
the course of development. Several studies indicate that after the first few months of infancy,
during which stress reactivity is observed, a period of hyporesponsiveness of the stress
system occurs, coinciding with the emergence of the diurnal rhythm of the HPA axis [183,
210–213]. Factors like sleep patterns and quality of caregiving are proposed to underlie this
normative developmental shift, which may persist from 2 months until midway through the
second year of life [183, 211–213]. Interestingly, the effects of prenatal stress on infant
cortisol response observed in the study by Tollenaar et al. [182] appear to follow this shift,
with higher prenatal stress predicting hyperactivity at 5 weeks, and hypoactivity at 2 and 12
months. Additional developmental changes in HPA axis functioning may occur as a result of
puberty [214, 215]. Second, activity of the HPA axis may differ depending upon whether
stressors are acute or chronic. Exposure to prenatal stress may result in a more reactive HPA
axis initially, but prolonged hyperactivity may eventually result in downregulation of the
system, with a dampening of diurnal cortisol output and hyporeactivity to stress later in life
[183, 216, 217]. Support for this phenomenon is evident in the patterns of hypocortisolism
observed in children and adults exposed to severe or chronic stress [183, 217]. Two of the
studies discussed above examined diurnal cortisol output in 10-year-old [191] and 15-yearold [192] children drawn from the same longitudinal cohort study. While there were too few
children participating in both the 10 and 15-year follow-ups to directly test the possibility of
a shift from hyperactivity to hypoactivity of the axis, the pattern of findings is consistent
with such a shift.
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In terms of their characterizations of prenatal stress, investigations have focused on maternal
psychological functioning or maternal cortisol output. A primary assumption of this research
is that elevations in maternal and placental stress hormones mediate the effects of prenatal
psychological stress on fetal HPA axis development. However, results of studies examining
links between maternal prenatal psychological stress and stress hormones, primarily
maternal cortisol, are equivocal at best (see ref. 218 for a systematic review). The
paradoxical increase in maternal stress hormones and decrease in psychological and
physiological responsiveness to stress as gestation advances may partly explain why
psychological and biological markers of maternal stress are not reliably coupled. Most
investigations have focused on individual differences between average levels of maternal
prenatal psychological stress and stress hormones, examining whether mothers with higher
psychological stress also exhibit higher stress hormone levels. A more precise measure of
the concordance between psychological and physiological stress may be intra-individual
associations between these parameters of stress. One research group has reported positive
covariation between prenatal maternal negative mood and salivary cortisol over the course of
the day [219, 220]. There is also some evidence that prenatal maternal psychological stress
alters overall trajectories of cortisol output over gestation [221] and is reflected in integrated
measures of cortisol activity, such as cortisol measured in hair [222]. It is additionally
plausible that prenatal maternal psychological stress influences fetal HPA axis development
through mechanisms other than prenatal maternal cortisol, such as placental CRH exposures
or vascular or immune channels [223–227]. Research must continue to evolve and utilize a
more comprehensive approach in understanding the variety of stress exposures that may
influence fetal HPA axis development.

Author Manuscript

Careful consideration should also be given to factors that may moderate fetal exposure to
prenatal stress. Particularly important may be the timing of prenatal stress. It is known that
prenatal exposures during different gestational intervals exert differential effects, depending
on the fetal developmental processes occurring at the time [24, 171, 228]. Furthermore,
since maternal stress responsiveness is downregulated as gestation advances, stressful events
experienced early in pregnancy trigger greater maternal stress responses and therefore have
the potential to exert greater influence on the fetus than stressors experienced later in
gestation [72–78, 229, 230].

Author Manuscript

Fetal sex also may moderate the programming effects of prenatal stress on the fetal HPA
axis. Substantial evidence indicates that there are sex-specific trajectories of fetal
development, related to the response of the placenta to stress [231, 232]. Female and male
fetuses appear to exhibit contrasting growth strategies, whereby in response to stress
exposures, female fetuses adjust their growth and male fetuses do not [232, 233]. This may
be because the female placenta is more sensitive and responsive to changes in cortisol
concentrations during gestation as compared to the male placenta. For example, in the
presence of maternal inflammatory disease, female placental 11β-HSD-2 expression and
activity are significantly decreased, with corresponding elevations in circulating cortisol
levels and reductions in birthweight [234]. Conversely, male placental GR mRNA
expression is increased, with no changes observed in 11β-HSD-2 activity, cortisol level, or
growth [234]. Similarly, Osei-Kumah et al. [235] measured alterations in placental gene
expression as a function of maternal inflammatory disease and observed many more gene
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alterations in female placentae as compared to male placentae. Thus far, the potential
moderating effect of fetal sex on the relationship between prenatal stress and HPA axis
outcomes has been largely unexamined. Several studies document stronger effects of
maternal prenatal stress on cortisol output in female children [181, 187, 191]. Additionally,
van den Bergh et al. [193] reported an effect of maternal prenatal anxiety on diurnal salivary
cortisol profiles in both sexes, but the altered cortisol profile was associated with depressive
symptoms only in female adolescents. It is clear that additional research is needed to
understand the precise mechanisms by which various prenatal stressors influence patterns of
HPA axis development and factors that may moderate these effects.

7.

Five-year view

Author Manuscript

During the fetal period, experiences and exposures shape developing organ systems to
promote optimal functioning in life after birth. A growing number of prospective,
longitudinal studies have assessed links between prenatal stress and later developmental
outcomes, including HPA axis functioning. The primary focus of these existing
investigations has been exposure to elevations in maternal psychological distress and
maternal cortisol. Additional stress signals likely shape the developing fetal HPA axis.
Among these is placental CRH, a direct and integrative index of fetal exposure to a variety
of stressors. Placental CRH is upregulated by maternal and fetal cortisol, catecholomines,
proinflammatory cytokines, and vascular changes [70, 137, 138, 153, 154, 156] and appears
to directly influence fetal pituitary-adrenal growth and steroidogenesis [115–119]. Future
research should focus on placental CRH as an indicator of prenatal stress-induced alterations
in HPA axis functioning.
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An emerging and promising area of research suggests that gene-environment interactions
may also mediate the effects of prenatal stress on HPA axis development and function.
Epigenetic mechanisms involve changes in gene expression, which can arise during critical
periods of development in response to environmental exposures and may remain stable into
adulthood [18, 236, 237]. Increasing evidence suggests that prenatal stress is associated with
epigenetic change in HPA axis genes, particularly methylation in the promoter region of
NR3C1, the gene encoding the glucocorticoid receptor [238]. As previously mentioned, GRs
play a critical role in negative feedback inhibition of the HPA axis response. For example,
increased methylation of NR3C1 results in decreased expression of hippocampal GR,
dampening of HPA axis negative feedback, and a prolonged increase in circulating
glucocorticoid levels in rodents [146]. In adult humans, childhood abuse is associated with
increased promoter methylation and decreased expression at the NR3C1 gene in
hippocampal brain tissue [239].

Author Manuscript

Several studies have examined links between prenatal stress and peripheral measures of
NR3C1 methylation. Higher levels of prenatal maternal depression and anxiety [240, 241]
and diurnal cortisol output [241] were associated with increased methylation of NR3C1 in
cord blood, which predicted increased infant cortisol response to stress at 3 months [240].
Elevations in prenatal maternal depression and anxiety also predicted increased placental
NR3C1 and 11β-HSD-2 methylation [242]. One study considered the impact of prenatal
exposure to chronic stress and war-related trauma in a sample of mothers and infants in the
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Democratic Republic of Congo, documenting methylation of multiple genes regulating HPA
axis function (CRH, CRHBP, NR3C1, and FKBP5) in maternal blood, cord blood, and
placental tissue [243]. There is some evidence that the effects of prenatal-induced epigenetic
modifications may extend into adolescence and adulthood [244] and may be further
transmitted across multiple generations [245]. While the relationship between epigenetic
variation in the periphery and in brain is currently unknown, these findings encourage
further examination of the interactive influence of genes and environmental stressors on
HPA axis development.
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Finally, future research could examine how the pre and postnatal environments act
independently or synergistically to shape development of the HPA axis. A few investigations
have considered the additive or moderating effects of the postnatal environment on stress
responsiveness [186, 246–249]. Kaplan et al. [249] reported that postnatal maternal
sensitivity moderated the effects of prenatal maternal mood disorder on baseline cortisol in
4-month-old infants. Specifically, infants of mothers with a prenatal maternal mood disorder
exhibited elevated cortisol only in context of low maternal sensitivity, and infants of mothers
without a prenatal maternal mood disorder had low cortisol regardless of maternal
sensitivity. In this sense, the effects of prenatal stress may be amplified in context of an
impoverished postnatal environment or may be attenuated in a high-quality environment.
The predictive adaptive response hypothesis alternatively posits that developmental
adjustments made in response to prenatal stress signals are adaptive when the actual
postnatal environment matches that predicted by the prenatal environment [4, 5, 8].
Consistent with this argument, one study indicated that infants exhibited more extreme
salivary cortisol responses to a maternal separation stressor, reflected in an extended
response and lack of recovery, if maternal prenatal and postnatal depressive symptom levels
were discordant [247]. Infants exposed to consistently low levels of depressive symptoms
exhibited the most normative profiles of response and recovery from the stressor.
Collectively, these studies provide additional evidence that the developing fetal HPA axis is
sensitive to and shaped by the conditions of the intrauterine environment, but additionally
suggest that the effects of prenatal stress exposures should be considered in the context of
the postnatal environment.

Author Manuscript

While the multiple complex mechanisms regulating the development of the fetal HPA axis
are not fully understood, studies reviewed here provide strong evidence that prenatal stress
exposures shape the developing axis and exert persisting influence on its function into
adulthood. Given the fundamental role of the HPA axis in regulating many of the body’s
homeostatic systems and associations between HPA axis dysregulation and disease [9–15],
programming of the axis is a plausible mechanism underlying links between early exposures
and later health outcomes, including risk for cardiovascular, metabolic, immune, and mental
disorders [3, 16–22]. The HPA axis is an ancient physiological system that has been
maintained by natural selection and conserved across species, promoting adaptation and
survival in response to environmental threats [250]. The sensitivity and plasticity of the
developing fetal HPA axis stress to exposures signaling the state of the external environment
also appears to be deeply rooted in human evolutionary history [251] and would have been
of value to our ancestors, ensuring offspring would be well-suited to survive in a presumably
limiting and hostile environment [4, 5]. However, activation of this same stress reponse
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system may no longer be adaptive in modern environments characterized by urbanization,
nutritional abundance, and a sedantary lifestyle, in which stressors are frequent and chronic
but seldom require fight or flight [252, 253]. Stress related-alterations in physiology may
instead prove detrimental to health and confer risk for disease. Interventions focused on
improving the quality of maternal and fetal health in utero may assist in closing the gap
between the stress responses conferred on us by our evolutionary past and those better suited
for modern day circumstances.
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•

The developmental origins of disease or fetal programming model predicts
that prenatal experiences have life-long consequences for physical and
psychological health.

•

The hypothalamic-pituitary-adrenal (HPA) axis mobilizes the body’s physical
and psychological resources in response to stress and regulates many
homeostatic systems. Programming of the developing fetal HPA axis is
proposed as a primary mechanism by which early experiences are linked to
later disease risk.

•

The placenta is largely responsible for the massive changes that occur in both
the maternal and developing fetal stress systems during the prenatal period.
An integrated maternal-placental-fetal steroidogenic unit regulates the
prenatal endocrine milieu.

•

The precise mechanisms by which prenatal stressors may shape the nascent
fetal HPA axis are not fully understood. In addition to cortisol, placental CRH
is a promising candidate, because it is a signal that integrates a variety of
stressors and appears to directly influence fetal pituitary-adrenal activity.

•

Prospective, longitudinal investigations have provided evidence that
elevations in maternal prenatal psychological stress and cortisol are associated
with alterations in HPA axis functioning, reflected in diurnal rhythms and
responses to stress. Findings are observed in the neonate, infant, child,
adolescent, and adult.

•

Prenatal stress is associated with both hyperactivity or hypoactivity in HPA
axis functioning. It is also plausible that these differential effects reflect
meaningful developmental patterns.

•

Several factors may moderate the effects of prenatal stress on HPA axis
function, including the time of gestation at which the stressor occurs and the
sex of the fetus.

•

An emerging literature suggests that epigenetic changes in HPA axis genes
may mediate the effects of prenatal stress on fetal HPA axis development and
function.

•

The effects of prenatal stress may be amplified or attenuated as a function of
the postnatal environment. Alternatively, the predictive adaptive response
hypothesis posits that developmental adjustments made in response to
prenatal stress are adaptive if there is a match between the prenatal and
postnatal environments.
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Figure 1.

Schematic representation of the hypothalamic-pituitary-adrenal (HPA) axis. In response to
stress, corticotropin-releasing hormone (CRH) is synthesized in the paraventricular nucleus
(PVN) of the hypothalamus and released into the hypophyseal portal blood. CRH binds to its
receptors on pituitary corticotropes, stimulating the release of adrenocorticotrophic hormone
(ACTH). Circulating ACTH binds to its receptors in the adrenal cortex and stimulates the
release of cortisol, which mobilizes body systems to respond to the stressor. Elevated
circulating cortisol inhibits further HPA axis activity (blue squares) by binding to its two
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receptor types, glucocorticoid receptors (GRs) and mineralocorticoid receptors (GRs), at the
level of the hypothalamus, pituitary, and hippocampus. CRH-producing neurons in the PVN
of the hypothalamus are innervated by afferent projections from multiple brain regions (blue
and green circles), including the amygdala, which provides excitatory input, and the
prefrontal cortex and hippocampus, which provide inhibitory input.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; GR:
glucocorticoid receptor; MR: mineralocorticoid receptor; PVN: paraventricular nucleus
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Increases in hypothalamic-pituitary-adrenal and placental hormones in maternal circulation
over gestation. Points represent mean levels of these hormones at each gestational interval.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; GA:
Gestational age
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Figure 3.
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Schematic representation of the maternal-placental-fetal steroidogenic unit. Placental
corticotropin-releasing hormone (CRH) influences both maternal and fetal stress hormone
production. In the maternal compartment, increases in placental CRH promote increased
synthesis and release of ACTH and cortisol. Maternal cortisol in turn stimulates placental
CRH production, generating a positive feedback loop (green lines). The placental enzyme
11β-hydroxysteroid dehydrogenase 2 (11β-HSD-2) oxidizes maternal cortisol into cortisone,
but it is only a partial barrier, with some maternal cortisol entering fetal circulation. The
developing fetal hypothalamic-pituitary-adrenal axis is regulated in part by maternal cortisol
and placental CRH. Maternal cortisol may inhibit fetal pituitary ACTH release. Placental
CRH likely stimulates production of fetal cortisol, both by increasing fetal adrenal
responsiveness to ACTH and by direct stimulation of the adrenal. Increased fetal cortisol
would in turn stimulate placental CRH production, constituting a second positive feedback
loop (green lines). The massive amounts of hormones produced by the maternal-placentalfetal unit benefit both mother and fetus and influence the timing of parturition.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; 11β-HSD-2:
11β-hydroxysteroid dehydrogenase 2
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Time table summarizing fetal hypothalamic-pituitary adrenal (HPA) axis development.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; 11β-HSD-2:
11β-hydroxysteroid dehydrogenase 2
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Studies documenting associations between prenatal stress and postnatal HPA axis functioning
Study

Author Manuscript
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Sample

Prenatal Exposure

HPA Axis Outcome

Findings

Davis et al.
(2011)

116 women and
their neonates

Maternal cortisol and
psychosocial stress at 15, 19, 25,
31, and 37 weeks’ gestation

Salivary cortisol response to
heel-stick blood draw at
approximately 24 hours after
birth; samples collected prestressor and at 20 and 40 min
post-stressor

Elevated maternal cortisol
from 21–35 weeks’ gestation
was associated with larger
neonatal cortisol response;
strongest effects were at 25
weeks’ gestation

Field et al.
(2004)

119 women and
their neonates

Maternal depressive symptoms
and first morning urinary
cortisol at approximately 20
weeks’ gestation

Urinary cortisol within 24 hours
of delivery

Neonates of mothers with
elevated depressive
symptoms had higher
cortisol levels

Lundy et al.
(1999)

63 women and
their neonates

Maternal depressive symptoms
and urinary cortisol during third
trimester (M = 32 weeks’
gestation, range = 27–35 weeks’
gestation)

Urinary cortisol within 24 hours
of delivery

Neonates of mothers with
elevated depressive
symptoms had higher
cortisol levels

Marcus et al.
(2011)

154 women and
their neonates

Maternal depressive symptoms
at 28, 32, and 37 weeks’
gestation

ACTH and cortisol levels from
umbilical cord artery blood at
delivery

Neonates exposed to elevated
levels of maternal depressive
symptoms had higher ACTH
levels than neonates exposed
to low-stable depressive
symptoms

Braithwaite,
Murphy, &
Ramchandani
(2016)

88 women and
their 2–4-monthold infants

Maternal depressive symptoms
during second or third trimester
(M = 28 weeks’ gestation; range
= 15–41 weeks’ gestation)

Salivary cortisol response to
inoculation; samples collected
anytime in day before stressor,
immediately after stressor, and
at 20 and 40 min post-stressor

No association between
maternal depressive
symptoms and infant cortisol
response

Grant et al.
(2009)

88 women and
their 7-month-old
infants

Maternal anxiety symptoms
assessed via structured clinical
interview during last trimester of
pregnancy; women classified as
meeting (or not meeting) criteria
for prenatal anxiety disorder
during last six months of
pregnancy

Salivary cortisol response to the
still-face procedure; samples
collected at pre-stressor and at
15, 25, and 40 min post-stressor

Infants of mothers without
prenatal anxiety disorders
exhibited decrease in cortisol
from 25–40 minutes poststressor, while infants of
mothers with prenatal
anxiety disorders exhibited
non-significant increase in
cortisol across this interval

O’Connor et al.
(2012)

125 women and
their 17-month-old
infants

Amniotic fluid cortisol during
second or third trimester (M =
17 weeks’ gestation; range =
15–37 weeks’ gestation)

Salivary cortisol response to a
maternal separation paradigm;
samples collected pre-stressor
and at 20 minutes post-stressor

Infants exposed to higher
levels of amniotic fluid
cortisol exhibited higher prestress cortisol levels and
blunted stress responses
(slight decrease over
stressor)

Rash et al.
(2016)

254 women at
their 6-month-old
infants

Maternal diurnal salivary
cortisol output (4 samples over 2
consecutive days) and
psychosocial stress at 15 weeks’
and 32 weeks’ gestation

Salivary cortisol response to set
of structured laboratory
frustration tasks at 6 months;
samples collected pre-stressor
and at approximately 15 minutes
post-stressor

Infants who exhibited a
decreased in cortisol in
response to the task (as
opposed to an increase) were
exposed to a flatter maternal
diurnal profile (less of a
decline in cortisol over the
course of the day) at 15
weeks’ gestation

Stroud et al.
(2016)

153 women and
their 1-month-old
infants

Maternal depressive symptoms
assessed via structured clinical
interview at approximately 23,
30, and 36 weeks’ gestation;
women classified as exhibiting
prenatal depressive disorder,
preconception-only depressive

Salivary cortisol response to
NICU Network Neurobehavioral
Scale; samples collected prestressor, end of stressor, and at
20 and 40 minutes post-stressor

Infants of mothers with
prenatal depressive disorders
exhibited higher baseline
cortisol levels and higher
cortisol response than infants
of mothers with preconception only or no
depressive disorders (effect

Neonate

Infant
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disorder, or no depressive
disorder

Tollenaar et al.
(2011)

Findings
was driven by female
infants); among infants of
mothers with prenatal
depressive disorders,
decreased placental 11βHSD-2 methylation
associated with increased
baseline cortisol levels

173 women and
their infants
(assessed at 5
weeks, 8 weeks, 5
months, and 12
months)

Maternal anxiety, daily hassles,
pregnancy related anxiety, and
dirunal salivary cortisol output
(5 samples per day over 2
consecutive days) during third
trimester (M = 37 weeks)

Salivary cortisol response to a
bathing session at 5 weeks,
vaccination at 8 weeks, still-face
procedure at 6 months, and
maternal separation paradigm at
12 months; samples collected
pre-stressor and at 25 and 40
minutes post-stressor

Higher pregnancy-related
anxiety predicted higher
infant cortisol response to
stressor at 5 weeks and lower
cortisol response to stressors
at 8 weeks and 12 months

de Bruijn et al.
(2009)

103 women and
their 2–5-year-old
children

Maternal anxiety and depressive
symptoms at 12, 24, and 36
weeks’ gestation; children
whose mothers scored above a
standardized cutoff or higher
than 1 SD above the sample
mean on one of the three
measurements of anxiety or
depression at any of the
gestational intervals classified as
the prenatally exposed group

Salivary cortisol response to a
mother-child play task and a
frustration task; samples
collected at start of home visit,
and at 22 minutes after each task

No differences in response
patterns between prenatally
exposed and non-exposed
children, with both groups
showing a decrease in
cortisol levels over the tasks;
among female children,
higher overall cortisol levels
in prenatally exposed; no
effects among male children

Gutteling, de
Weerth, &
Buitelaar (2004)

24 women and
their 4–6-year-old
children

Maternal pregnancy-related
anxiety, daily hassles, perceived
stress, and early morning
cortisol levels at 15–17 weeks’
gestation; children placed in low
and high prenatal stress groups
by median split for each of the
four prenatal stress measures

Salivary cortisol response to
vaccination; samples collected
pre-stressor and at 15, 20, 25,
and 30 minutes post-stressor

Higher maternal prenatal
daily hassles, pregnancyrelated anxiety, and early
morning cortisol levels were
associated with higher
overall child cortisol levels

Gutteling, de
Weerth, &
Buitelaar (2005)

29 women and
their 5-year-old
children

Maternal pregnancy-related
anxiety, daily hassles, perceived
stress, and early morning
cortisol levels at 15–17 weeks’
gestation; children placed in low
and high prenatal stress groups
by median split for each of the
four prenatal stress measures

Diurnal salivary cortisol output
on weekend day (5 samples over
the day), on the first day of
school (4 samples over the day),
and on a school day one week
later (4 samples over the day)

Higher maternal pregnancyrelated anxiety and early
morning cortisol levels were
associated with higher
overall child cortisol levels
on school days

MartinezTorteya et al.
(2016)

N = 119 women
and their 10-yearold children

Third trimester (M = 33 weeks’
gestation) maternal report of
exposure to intimate partner
violence (IPV) during pregnancy

Salivary cortisol response to
Trier Social Stress Test for
Children; samples collected prestressor and at 20 and 40
minutes post-stressor

Identified three profiles of
child cortisol response:
consistently low levels,
consistently moderate levels,
and consistently high levels
with increase from prestressor to 20 min poststressor; exposure to
maternal prenatal IPV
increased likelihood of
membership in high response
group, as compared to
consistently low and
moderate response groups

74 women and
their 10-year-old
children

Maternal anxiety and depressive
symptoms at 18 and 32 weeks’
gestation

Diurnal salivary cortisol output
(4 samples per day over 3
consecutive days

Higher maternal prenatal
anxiety at 32 weeks’
gestation predicted higher
child awakening cortisol
levels

Child
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O’Connor et al.
(2005)

Adolescent
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Huizink et al.
(2008)

121 14-year-old
twin pairs of
Finnish women
pregnant during
the Chernobyl
disaster and 157
14-year-old twin
pairs of women
who were
pregnant one year
after the disaster

Exposed or not exposed to
Chernobyl disaster during
pregnancy

Salivary cortisol levels measured
once upon arrival to a laboratory
visit

Adolescents whose mothers
were in their second or third
trimesters during the
Chernobyl disaster had
higher cortisol levels as
compared to the reference
group

O’Donnell et al.
(2013)

899 women and
their 15-year-old
adolescents

Maternal anxiety and depressive
symptoms at 18 and 32 weeks’
gestation

Diurnal salivary cortisol output
(4 samples per day over 3
consecutive days)

Higher maternal prenatal
anxiety and depressive
symptoms were associated
with a lower cortisol
awakening response and a
flatter diurnal decline
(smaller decrease) in cortisol
levels in adolescents; effects
similar at 18 & 32 weeks’
gestation

Van den Bergh
et al. (2008)

58 women and
their 14–15-year
old adolescents

Maternal anxiety symptoms at
12–22, 23–32, and 32–40
weeks’ gestation

Diurnal salivary cortisol output
(3 samples over one day)

Elevated prenatal maternal
anxiety at 12–22 weeks’
gestation was associated with
a flatter diurnal decline
(smaller decrease) in cortisol
levels in adolescents; in
female adolescents this
cortisol profile was
associated with higher
depressive symptoms

31 young adults
whose mothers
reported
experiencing a
major negative life
event during
pregnancy and a
control group of
30 age-matched
young adults

Maternal prenatal life events
were obtained retrospectively by
young adult children in
communication with mothers at
time of the assessment

ACTH and serum cortisol
responses to Trier Social Stress
Test (samples pre-stressor and at
15, 25, 35, and 105 minutes
post-stressor), pharmacological
stimulation of pituitary
(ACTH1–24 test), and diurnal
salivary cortisol output (20
samples over one weekday)

Prenatal stress-exposed
group exhibited lower
baseline cortisol levels and
greater increases in cortisol
(baseline to peak) in
response to stressor, as well
as trend-level higher ACTH
levels during the stressor;
prenatal stress-exposed
group exhibited lower
cortisol levels during
ACTH1–24 test; no
differences in diurnal cortisol
output between the two
groups

Adult
Entringer et al.
(2009)
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